Early Stage Medical Device Company Appoints New VP Medical Affairs

COLUMBIA, S.C. -- Flow MedTech, Inc., an early-stage company developing an implantable medical device to prevent strokes in people with irregular heart rhythms, announces the appointment of Senthil Thambidorai, MD, FHRS, as Vice President of Medical Affairs. Dr. Thambidorai completed a Cardiac Electrophysiology Fellowship at Cleveland Clinic in Ohio and a Cardiology Fellowship at the Creighton University-Department of Medicine in Nebraska. Dr. Thambidorai received his Doctor of Medicine, Bachelor of Medicine, Bachelor of Surgery from Kilpauk Medical College in India.

David Menzies | 919-274-6862 Fiction Writer and Public Relations Consultant  | www.daviddeanmenzies.com"With Dr. Thambidorai's extensive training in left atrial appendage closures and experience with left atrial appendage closure devices, he is an incredible addition as well as a strong asset for our team," said Arnab Chakraborty, Chief Product Officer and Chairman, Flow MedTech.

Dr. Thambidorai will lead Flow MedTech's efforts by providing clinical input and vision during the research and development phase. He will also facilitate strategic partnerships to strengthen and further Flow MedTech's position in the left atrial appendage closure market. His leadership to the Flow MedTech team will ensure the delivery of key objectives.

"We are thrilled to have Dr. Thambidorai join the Flow MedTech team. He brings a tremendous amount of perspective due to his experiences of implanting left atrial appendage closure devices in the Dallas/Fort Worth area," said Christine Hang, Chief Executive Office, Flow MedTech. "It was important to us to bring someone on board who has the hands-on clinical experience to lead our medical affairs. Dr. Thambidorai will add profound value as we continue the development of Flow MedTech's technology."

Dr. Thambidorai will also continue his roles as the Regional Director of Electrophysiology for HCA North Texas, cardiologist and cardiac electrophysiologist in Fort Worth, TX, and a part of the academic core faculty for the Internal Medicine Residency Program at the University of North Texas in Fort Worth, TX. Dr. Thambidorai is a member of the American College of Cardiology and American Heart Association. He is the author of more than 13 peer-reviewed articles and more than 25 scientific presentations at national and international forums.

About Flow MedTech, Inc.

Flow MedTech, Inc., is an early-stage medical device startup and a member of Health Wildcatters accelerator, SC Launch, and PriMed accelerator. The technology is focused on preventing strokes in patients with the most common irregular heart rhythm, known as atrial fibrillation. The device targets the left atrial appendage (LAA), which is known to be a breeding ground for clot formations. 90% of clots in the brain have been traced to the LAA. The patent-pending technology, developed by Georgia Tech biomedical engineering alumni, prevents clot formation by blocking blood flow into the LAA and thus reducing the risk of strokes. The development of this device is supported by cardiac faculty from the Emory School of Medicine as well as a key opinion leader, Dr. Horst Sievert.

Startup TechWire - Reporting on business, innovation, and education for America's vibrant startup community | David Menzies | 919-274-6862 | Writer and Public Relations Consultant | Editor StartupTechWire.com | startuptechwire@gmail.com | www.daviddeanmenzies.com